TIDMAREC

RNS Number : 1776C

Arecor Therapeutics PLC

09 June 2023

Arecor Therapeutics plc

("Arecor", the "Company" or the "Group")

AGM STATEMENT

A year of delivery and execution across the Arecor business: building a broad platform for long-term success

Cambridge, UK, 9 June 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, provides the following update ahead of its Annual General Meeting, to be held today at 9.30 am at the offices of Covington & Burling LLP, 22 Bishopsgate, London EC2N 4BQ.

At the meeting, Andrew Richards, Non-Executive Chair, will make the following statement:

"Arecor experienced a successful 2022, and despite a background of major global challenges which impacted the financial markets and all segments of industry including the pharmaceutical sector, we were encouraged by Arecor's progress towards its ambition of building a significant self-sustaining biopharmaceutical company.

"New partnerships with leading pharmaceutical companies strengthened our reputation as an innovator that pharma and biopharma can work with and clearly demonstrate the strength and relevance of our platform and intellectual property. These partnerships provide a route to multiple potential ongoing revenue streams through licenses and through pre-license technology partnerships. Our existing partnerships continue to progress towards commercialisation and we see significant further opportunities to apply our technology in ready-to-use and ready-to-administer hospital care medicines and to partner programmes across a range of indications and formulations.

"Within our own portfolio of insulin-based products, we successfully completed a further Phase I clinical trial in diabetes for our ultra-rapid acting insulin candidate AT247, which clearly showed that it possesses characteristics that facilitate a fully closed loop artificial pancreas, with optimal automated delivery of insulin. Furthermore, we closed the year with initiation of a second Phase I clinical trial for AT278, an ultra-rapid acting, ultra-concentrated insulin candidate, in Type 2 diabetic patients.

"In addition, we successfully raised GBP6 million to acquire Tetris Pharma, providing Arecor with a revenue-generating marketing, sales and distribution capability and greater optionality in the future both for our specialty products franchise and potential partner products. The acquisition, and lead product Ogluo(R), bring the opportunity to accelerate our commercially driven strategy.

"Looking forward, we will continue to build on the solid platform we have established and believe 2023 will be a year of accelerated delivery across the key areas of our business as we continue to build long-term value for our shareholders."

Further information about the AGM can be found in the investor centre section of our website https://arecor.com/investor-centre/shareholder-information/

-ENDS-

For more information, please contact:

 
 Arecor Therapeutics plc                  www.arecor.com 
 Dr Sarah Howell, Chief Executive         Tel: +44 (0) 1223 426060 
  Officer                                  Email: info@arecor.com 
 
 Susan Lowther, Chief Financial Officer   Tel: +44 (0) 1223 426060 
                                           Email: info@arecor.com 
 
 Mo Noonan, Communications                Tel: +44 (0) 7876 444977 
                                           Email: mo.noonan@arecor.com 
 
 Panmure Gordon (UK) Limited (NOMAD       Tel: +44 (0) 20 7886 2500 
  and Broker) 
  Freddy Crossley, Emma Earl (Corporate 
  Finance) 
  Rupert Dearden (Corporate Broking) 
 
 Consilium Strategic Communications       Tel: +44 (0) 20 3709 5700 
  Chris Gardner, David Daley, Lindsey      Email: arecor@consilium-comms.com 
  Neville

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat(TM), we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat(TM) platform is supported by an extensive patent portfolio.

For further details please see our website, www.arecor.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

AGMFLFLARVITIIV

(END) Dow Jones Newswires

June 09, 2023 02:00 ET (06:00 GMT)

Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Arecor Therapeutics Charts.
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Arecor Therapeutics Charts.